Table 4. Raw data for meta-analysis on improvement in psychiatric illness with the use of psilocybin.
Study | Events | Sample size | Outcome | SE | CI lower | CI upper | Study ID | Rate | CI lower | CI upper |
Carhart-Harris et al. 2016 [26] | 19 | 20 | 0.95 | 0.22 | 0.52 | 1.34 | 10 | 95 | 42.72 | 42.72 |
Carhart-Harris et al. 2017 [17] | 19 | 19 | 1 | 0.23 | 0.55 | 1.45 | 9 | 100 | 44.97 | 44.97 |
Davis et al. 2021 [32] | 17 | 24 | 0.71 | 0.17 | 0.37 | 1.04 | 8 | 70.83 | 33.67 | 33.67 |
Ross et al. 2016 [33] | 20.3 | 29 | 0.7 | 0.16 | 0.39 | 1.00 | 7 | 70 | 30.45 | 30.45 |
Griffiths et al. 2016 [4] | 41 | 51 | 0.80 | 0.13 | 0.56 | 1.05 | 6 | 80.39 | 24.60 | 24.61 |
Larsen et al. 2017 [6] | 2 | 12 | 0.17 | 0.12 | -0.06 | 0.39 | 5 | 16.67 | 23.10 | 23.10 |
Johnson et al. 2014 [23] | 12 | 15 | 0.8 | 0.23 | 0.35 | 1.25 | 4 | 80 | 45.26 | 45.26 |
Mason et al. 2019 [11] | 50 | 50 | 1 | 0.14 | 0.72 | 1.28 | 3 | 100 | 27.72 | 27.72 |
Stroud et al. 2018 [12] | 17 | 17 | 1 | 0.24 | 0.52 | 1.48 | 2 | 100 | 47.54 | 47.54 |
Summary | 197.3 | 237 | 0.77 | 0.11 | 0.55 | 0.99 | 1 | 76.98 | 21.68 | 21.68 |